OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2025. The company reported a net loss of $15.4 million, compared to a net loss of $14.1 million in the same quarter of 2024. Research and development expenses rose to $12.6 million from $10.8 million in the previous year, driven by increased clinical trial, outsourced manufacturing, and research expenses. General and administrative expenses saw a slight increase to $3.7 million from $3.6 million, attributed to higher personnel-related costs and professional service fees, partially offset by a reduction in legal expenses. The company's cash and cash equivalents stood at $83.4 million as of June 30, 2025, expected to support operations into the fourth quarter of 2026. OnKure is advancing its lead asset, OKI-219, with the PIKture-01 phase 1 clinical trial on track for data release in the fourth quarter of 2025. The trial includes new expansion arms to assess OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer and with trastuzumab and tucatinib in HER2+ metastatic breast cancer. CEO Nicholas Saccomano expressed optimism about the progress in developing OKI-219, focusing on broadening its application in breast cancer treatment.